Brain metastasis responding to gefitinib alone

Oncology

Volumn 67, Issue 2, 2004, Pages 174-178

  Poon, Annette N Y ^a   Ho, Simon S M ^a   Yeo, Winnie ^a   Mok, Tony S K ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Brain metastases; Chemotherapy; Gefitinib; Lung cancer; Metastases; Radiotherapy

Indexed keywords

CISPLATIN; GEFITINIB; PACLITAXEL;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CASE REPORT; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GINGIVAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 8344287552     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081005     Document Type: Article

References (26)

1. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P: Brain metastases in adenocarcinoma of the lung: Frequency, risk groups, and prognosis. J Clin Oncol 1988;6:1474-1480.
2. Coia LR: The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 1992;23:229-238.
3. Malacarne P, Santini A, Maestri A: Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology 1996;53:210-213.
4. Kantarjian H, Farha PA, Spitzer G, et al: Systemic combination chemotherapy as primary treatment of brain metastasis from lung cancer. South Med J 1984;77:426-430.
5. Nakagawa H, Fujita T, Izumimoto S, et al: Cisdiamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. II. Clinical effects. J Neurooncol 1993;16:69-76.
6. Matsumoto S, Yoshimoto A, Ohsaki A, et al: A case of complete remission in brain metastasis from lung adenocarcinoma with EAP (etoposide, adriamycin, cisplatin) (in Japanese). Gan To Kagaku Ryoho 1990;17:1933-1936.
7. Robinet G, Thomas P, Breton JL, et al: Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 2001;12:59-67.
8. Ushio Y, Arita N, Hayakawa T, et al: Chemotherapy of brain metastases from lung carcinoma: A controlled randomized study. Neurosurgery 1991;28:201-205.
9. Ranson M, Hammond LA, Ferry D, et al: ZD 1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of phase I trial. J Clin Oncol 2002;20:2240-2250.
10. Fukuoka M, Yano S, Giaccone G, et al: A multi-institutional randomised phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003;21:2237-2246.
11. Villano JL, Mauer AM, Vokes EE: A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol 2003;14:656-658.
12. Kvale PA, Simoff M, Prakash UB: Lung cancer. Palliative care. Chest 2003;123(1 suppl): 284S-311S.
13. Korfel A, Oehm C, von Pawel J, et al: Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation: A multicentre phase II study. Eur J Cancer 2002;38:1724-1729.
14. Antonadou D, Paraskevaidis M, Sarris G, et al: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002;17:3644-3650.
15. Christodoulou C, Bafaloukos D, Kosmidis P, et al; Hellenic Cooperative Oncology Group: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;12:249-254.
16. Quantin X, Khial F, Reme-Saumon M, et al: Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer 1999;26:35-39.
17. Quantin X, Pujol JL, Paris A, et al: Concomitant brain radiotherapy and high-dose ifosfamide in brain relapses of lung cancer. Ann Oncol 1997;8:311-313.
18. Lima CM, Chiappori A: Treatment of relapsed small-cell lung cancer - a focus on the evolving role of topotecan. Lung Cancer 2003;40:229-236.
19. von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
20. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the secondline treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090-2096.
21. Ebert BL, Niemierko E, Shaffer K, et al: Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 2003;8:69-75.
22. Abrey LE, Christodoulou C: Temozolomide for treating brain metastases. Semin Oncol 2001;28(4 suppl 13):34-42.
23. Milas L, Mason K, Hunter N, et al: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701-708.
24. Saleh MN, Raisch KP, Stackhouse MA, et al: Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999;14:451-463.
25. Robert F, Ezekiel MP, Spencer SA: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-3243.
26. Bianco C, Tortora G, Bianco R, et al: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8:3250-3258.